159 related articles for article (PubMed ID: 31755660)
1. Reduced PLCG1 expression is associated with inferior survival for myelodysplastic syndromes.
Shiseki M; Ishii M; Miyazaki M; Osanai S; Wang YH; Yoshinaga K; Mori N; Tanaka J
Cancer Med; 2020 Jan; 9(2):460-468. PubMed ID: 31755660
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of genes located within the common deleted region of del(20q) in patients with myelodysplastic syndromes.
Shiseki M; Ishii M; Okada M; Ohwashi M; Wang YH; Osanai S; Yoshinaga K; Mori N; Motoji T; Tanaka J
Leuk Res; 2019 Sep; 84():106175. PubMed ID: 31299412
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
Braun T; de Botton S; Taksin AL; Park S; Beyne-Rauzy O; Coiteux V; Sapena R; Lazareth A; Leroux G; Guenda K; Cassinat B; Fontenay M; Vey N; Guerci A; Dreyfus F; Bordessoule D; Stamatoullas A; Castaigne S; Terré C; Eclache V; Fenaux P; Adès L
Leuk Res; 2011 Jul; 35(7):863-7. PubMed ID: 21396711
[TBL] [Abstract][Full Text] [Related]
4. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
[TBL] [Abstract][Full Text] [Related]
5. Investigation of 305 patients with myelodysplastic syndromes and 20q deletion for associated cytogenetic and molecular genetic lesions and their prognostic impact.
Bacher U; Haferlach T; Schnittger S; Zenger M; Meggendorfer M; Jeromin S; Roller A; Grossmann V; Krauth MT; Alpermann T; Kern W; Haferlach C
Br J Haematol; 2014 Mar; 164(6):822-33. PubMed ID: 24372512
[TBL] [Abstract][Full Text] [Related]
6. Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.
Radujkovic A; Dietrich S; Andrulis M; Benner A; Longerich T; Pellagatti A; Nanda K; Giese T; Germing U; Baldus S; Boultwood J; Ho AD; Dreger P; Luft T
Int J Cancer; 2016 Sep; 139(6):1402-13. PubMed ID: 27170453
[TBL] [Abstract][Full Text] [Related]
7. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
[TBL] [Abstract][Full Text] [Related]
8. Utility of 5-Methylcytosine Immunohistochemical Staining to Assess Global DNA Methylation and Its Prognostic Impact in MDS Patients.
Chandra D; Tyagi S; Singh J; Deka R; Manivannan P; Mishra P; Pati HP; Saxena R
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3307-3313. PubMed ID: 29286224
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and survival in patients with myelodysplastic syndrome.
Savic A; Cemerikic-Martinovic V; Dovat S; Rajic N; Urosevic I; Sekulic B; Kvrgic V; Popovic S
Pathol Oncol Res; 2012 Jul; 18(3):681-90. PubMed ID: 22270865
[TBL] [Abstract][Full Text] [Related]
10. Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?
Greenbaum U; Joffe E; Filanovsky K; Oster HS; Kirgner I; Levi I; Raanani P; Avivi I; Manor E; Man-El G; Mittelman M
Eur J Haematol; 2018 Oct; 101(4):502-507. PubMed ID: 29956845
[TBL] [Abstract][Full Text] [Related]
11. Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course.
Courville EL; Singh C; Yohe S; Linden MA; Naemi K; Berger M; Ustun C; McKenna RW; Dolan M
Am J Clin Pathol; 2016 Apr; 145(4):459-66. PubMed ID: 27124938
[TBL] [Abstract][Full Text] [Related]
12. High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes.
Cheng CL; Hou HA; Jhuang JY; Lin CW; Chen CY; Tang JL; Chou WC; Tseng MH; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Br J Cancer; 2011 Sep; 105(7):975-82. PubMed ID: 21878936
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
[TBL] [Abstract][Full Text] [Related]
14. Purification of Bone Marrow Clonal Cells from Patients with Myelodysplastic Syndrome via IGF-IR.
He Q; Chang CK; Xu F; Zhang QX; Shi WH; Li X
PLoS One; 2015; 10(10):e0140372. PubMed ID: 26469401
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
16. Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.
Neukirchen-Strapatsas J; Tuechler H; Porta MD; Fenaux P; Guerci A; Haas R; Rossi M; Sapena R; Sperr WR; Strupp C; Stamatoullas A; Valent P; Germing U; Bennett JM
Leuk Res; 2019 Feb; 77():8-13. PubMed ID: 30605856
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-661 upregulation in myelodysplastic syndromes induces apoptosis through p53 activation and associates with decreased overall survival.
Kang SH; Choi JS
Leuk Lymphoma; 2019 Nov; 60(11):2779-2786. PubMed ID: 31056984
[TBL] [Abstract][Full Text] [Related]
18. Low RPS14 expression in MDS without 5q - aberration confers higher apoptosis rate of nucleated erythrocytes and predicts prolonged survival and possible response to lenalidomide in lower risk non-5q- patients.
Wu L; Li X; Xu F; Zhang Z; Chang C; He Q
Eur J Haematol; 2013 Jun; 90(6):486-93. PubMed ID: 23506134
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of EZH2 expression in myelodysplastic syndromes.
Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]